Intralesional Steroid Injection versus Erbium Yttrium Aluminium Garnet Laser Assisted Topical Corticosteroid Delivery in Treatment of Keloids.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR201909502724014

Enrollment

Registered

2019-09-02

Start date

2018-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases

Interventions

Fractional laser and topical steroids

Intralesional steroids injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients above the age of 18 years. both genders suffering of a diagnosed keloid scar in any part of their body will be enrolled in this study.

Exclusion criteria

Exclusion criteria: ? Pregnancy ? History of malignancy or radiation therapy ? Infections or viral skin diseases ? Immunosuppression ? Long-term systemic corticosteroid therapy ? The use of any treatment for the scar 6 months prior to the initiation of therapy.

Design outcomes

Primary

Measure	Time frame
aesthetic improvement of keloid scar	—

Secondary

Measure	Time frame
better quality of life for patients after treatment of keloid scars.	—

Countries

Egypt

Contacts

Public ContactNoha Hanafy

Researcher of Dermatology at National Research Centre

nohasamihanafy@gmail.com00201002009390

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026